secwatch.observer — SEC 8-K summary
======================================

Issuer:     CV Sciences, Inc. (CVSI)
CIK:        0001510964
Form:       8-K
Filed at:   2022-05-16T23:59:59+00:00
Accession:  0001510964-22-000040
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CV Sciences Q1 revenue $4.4M (-8% YoY); operating loss narrows to $1.5M on ERC benefit
--------------------------------------------------------------------------------

- Revenue $4.4M, down 8% from $4.8M in Q1 2021; units shipped up 3% offset by discounts and mix.
- Operating loss narrowed to $1.5M from $3.1M in Q1 2021; included $2.0M employee retention credit.
- Gross margin 26.0%, down from 32.4% in Q4 2021 sequentially; pressure from discounts/mix.
- Negative adjusted EBITDA $2.5M vs $2.3M a year ago; cash rose to $2.4M from $1.4M.
- Strategic review continues for possible merger/sale; launched new PlusCBD and OTC pain products.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1510964/000151096422000040/0001510964-22-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1510964/000151096422000040/cvsi-20220516.htm
  HTML page:      https://secwatch.observer/filing/0001510964-22-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer